Translator Disclaimer
9 March 2016 Cisplatin encapsulated nanoparticle as a therapeutic agent for anticancer treatment
Author Affiliations +
Proceedings Volume 9709, Biophotonics and Immune Responses XI; 97090T (2016)
Event: SPIE BiOS, 2016, San Francisco, California, United States
The knowledge of manipulating size of biomaterials encapsulated drug into nano-scale particles has been researched and developed in treating cancer. Cancer is the second worldwide cause of death, therefore it is critical to treat cancers challenging with therapeutic modality of various mechanisms. Our preliminary investigation has studied cisplatin encapsulated into lipid-based nanoparticle and examined the therapeutic effect on xenografted animal model. We used mice with tumor volume ranging from 195 to 214 mm3 and then few mice were grouped into three groups including: control (PBS), lipid platinum chloride (LPC) nanoparticles and CDDP (cis-diamminedichloroplatinum(II) at dose of 3mg cisplatin /kg body weight. The effect of the treatment was observed for 12 days post-injection. It showed that LPC NPs demonstrated a better therapeutic effect compared to CDDP at same 3mg cisplatin/kg drug dose of tumor size reduction, 96.6% and 11.1% respectively. In addition, mouse body weight loss of LPC, CDDP and PBS treated group are 12.1%, 24.3% and 1.4%. It means that by compared to CDDP group, LPC group demonstrated less side effect as not much reduction of body weight have found. Our findings have shown to be a potential modality to further investigate as a feasible cancer therapy modality.
© (2016) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Gusti Ngurah Putu Eka Putra, Leaf Huang, and Yih-Chih Hsu "Cisplatin encapsulated nanoparticle as a therapeutic agent for anticancer treatment", Proc. SPIE 9709, Biophotonics and Immune Responses XI, 97090T (9 March 2016);

Back to Top